Gynecomastia risk factors: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 13: Line 13:


* Drugs (12765)
* Drugs (12765)
** Spironolactone
** Spironolactone<ref name="pmid907238">{{cite journal| author=Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH| title=Pathophysiology of spironolactone-induced gynecomastia. | journal=Ann Intern Med | year= 1977 | volume= 87 | issue= 4 | pages= 398-403 | pmid=907238 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=907238  }} </ref>
** Cimetidine
** Cimetidine
** Recombinant Human Growth Hormone
** Recombinant Human Growth Hormone

Revision as of 16:36, 18 May 2017

Gynecomastia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gynecomastia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gynecomastia risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gynecomastia risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gynecomastia risk factors

CDC on Gynecomastia risk factors

Gynecomastia risk factors in the news

Blogs on Gynecomastia risk factors

Directions to Hospitals Treating Gynecomastia

Risk calculators and risk factors for Gynecomastia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

Risk Factors

Risk factors

The most potent risk factor in the development of gynecomastia is idiopathic often multifactorial.

Common Risk Factors

  • Idiopathic
  • Drugs (12765)
    • Spironolactone[1]
    • Cimetidine
    • Recombinant Human Growth Hormone
    • Estrogens
    • Human Chorionic gonadotropin
    • Anti-androgens
    • Gonadotropin Releasing hormone (GNRH) agonists
    • 5-alpha reductase inhibitors
    • Ketoconazole
    • steroids
    • INH
    • Digoxin[2]
  • Cirrhosis
  • Starvation and Refeeding
  • Male hypogonadism
  • Testicular neoplasms
  • Hyperthyroidism
  • Chronic Kidney disease
  • Tumors

Less Common Risk Factors

  • Feminizing adrenal tumors
  • Ectopic hCG
  • Disorders of sex development
  • Familial prepubertal gynecomastia

References

  1. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (1977). "Pathophysiology of spironolactone-induced gynecomastia". Ann Intern Med. 87 (4): 398–403. PMID 907238.
  2. Braunstein GD (1993). "Gynecomastia". N Engl J Med. 328 (7): 490–5. doi:10.1056/NEJM199302183280708. PMID 8421478.

Template:WH Template:WS